Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.

Détails

ID Serval
serval:BIB_A9C9384A62F6
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Périodique
Expert Review of Anti-infective Therapy
Auteur(s)
Manuel O., Perrottet N., Pascual M.
ISSN
1744-8336 (Electronic)
ISSN-L
1478-7210
Statut éditorial
Publié
Date de publication
2011
Volume
9
Numéro
11
Pages
955-965
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Cytomegalovirus (CMV) is generally considered the most significant pathogen to infect patients following organ transplantation. Significant improvements have been achieved in the management of CMV disease over recent years, especially since the introduction of oral drugs such as oral ganciclovir followed by valganciclovir (VGC), a prodrug of ganciclovir with enhanced bioavailability. Several randomized controlled trials have shown that VGC is an efficacious and convenient oral drug to prevent or treat CMV disease in solid-organ transplant recipients. In this article, we discuss the clinical and pharmacological experience with the use of VGC for the management of CMV in solid-organ transplant recipients. Finally, novel strategies to further reduce the incidence of CMV disease after transplantation are also reviewed.
Mots-clé
Administration, Oral, Antiviral Agents/pharmacokinetics, Antiviral Agents/therapeutic use, Cytokines/biosynthesis, Cytomegalovirus/drug effects, Cytomegalovirus/immunology, Cytomegalovirus Infections/drug therapy, Cytomegalovirus Infections/immunology, Cytomegalovirus Infections/</QualifierName> <QualifierName MajorTopicYN="N">, Drug Dosage Calculations, Ganciclovir/analogs & derivatives, Ganciclovir/pharmacokinetics, Humans, Immunity, Cellular/drug effects, Immunocompromised Host, Organ Transplantation, Practice Guidelines as Topic, Prodrugs/pharmacokinetics, Prodrugs/therapeutic use, Randomized Controlled Trials as Topic, Risk Factors, Transplantation Conditioning/adverse effects, Viral Load/drug effects, Virus Replication/drug effects
Pubmed
Web of science
Création de la notice
17/02/2012 17:00
Dernière modification de la notice
20/08/2019 15:14
Données d'usage